• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Liquidia Corporation (Amendment)

    2/14/24 4:18:49 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    SC 13G/A 1 tm245987d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND

    (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

     

    (Amendment No. 3)*

     

    Liquidia Corporation

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    53635D202

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      ¨ Rule 13d-1(c)

     

      x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 53635D202 13G Page 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Paul B. Manning

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    5,651,0751

    6

    SHARED VOTING POWER

    677,6462

    7

    SOLE DISPOSITIVE POWER

    5,651,0751

    8

    SHARED DISPOSITIVE POWER

    677,6462

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,328,7213

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.2%4

    12

    TYPE OF REPORTING PERSON*

    IN

     

    1 Consists of: (i) 279,330 shares of the Issuer’s common stock held by Mr. Manning, (ii) 4,852,464 shares of the Issuer’s common stock held by Paul and Diane Manning, JTWROS, (iii) 435,674 shares of the Issuer’s common stock held by PBM Capital Finance, LLC and (iv) 83,607 shares of common stock issuable upon the exercise of stock options within 60 days of December 31, 2023.
    2 Consists of: (i) 198,413 shares of the Issuer’s common stock held by PD Joint Holdings, LLC Series 2016-A and (ii) 479,233 shares of the Issuer’s common stock held by BKB Growth Investments, LLC.
    3 Consists of: (i) 279,330 shares of the Issuer’s common stock held by Mr. Manning, (ii) 4,852,464 shares of the Issuer’s common stock held by Paul and Diane Manning, JTWROS; (iii) 198,413 shares of the Issuer’s common stock held by PD Joint Holdings, LLC Series 2016-A; (iv) 479,233 shares of the Issuer’s common stock held by BKB Growth Investments, LLC; (v) 435,674 shares of the Issuer's common stock held by PBM Capital Finance, LLC and (vi) 83,607 shares of common stock issuable upon the exercise of stock options within 60 days of December 31, 2023.
    4 This percentage is calculated based upon 68,390,915 outstanding shares of Common Stock of the Issuer as of December 14, 2023, as reported in the Issuer’s Prospectus Supplement dated December 12, 2023 with respect to a public offering of the Issuer’s securities filed with the Securities and Exchange Commission on December 12, 2023.

     

     

     

     

    CUSIP No. 53635D202 13G Page 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    PD Joint Holdings, LLC, Series 2016-A

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    198,413

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    198,413

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    198,413

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.3%5

    12

    TYPE OF REPORTING PERSON*

    OO

     

    5 This percentage is calculated based upon 68,390,915 outstanding shares of Common Stock of the Issuer as of December 14, 2023, as reported in the Issuer’s Prospectus Supplement dated December 12, 2023 with respect to a public offering of the Issuer’s securities filed with the Securities and Exchange Commission on December 12, 2023.

     

     

     

     

    CUSIP No. 53635D202 13G Page 4 of 7 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    BKB Growth Investments, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    479,233

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    479,233

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    479,233

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.7%6

    12

    TYPE OF REPORTING PERSON*

    OO

     

    6 This percentage is calculated based upon 68,390,915 outstanding shares of Common Stock of the Issuer as of December 14, 2023, as reported in the Issuer’s Prospectus Supplement dated December 12, 2023 with respect to a public offering of the Issuer’s securities filed with the Securities and Exchange Commission on December 12, 2023.

     

     

     

     

    CUSIP No. 53635D202 13G Page 5 of 7 Pages

      

    Item 1.

     

    (a) Name of Issuer

    Liquidia Corporation

     

    (b) Address of Issuer’s Principal Executive Offices

    419 Davis Drive, Suite 100
    Morrisville, North Carolina 27560

     

    Item 2.

     

    (a) Name of Person Filing

    Paul B. Manning
    PD Joint Holdings, LLC, Series 2016-A
    BKB Growth Investments, LLC

     

    (b) Address of Principal Business Office or, if none, Residence

    c/o PBM Capital Group, LLC
    200 Garrett Street, Suite S
    Charlottesville, VA 22902

     

    (c) Citizenship

    Paul B. Manning is a United States Citizen.
    PD Joint Holdings, LLC, Series 2016-A is a Delaware limited liability company
    BKB Growth Investments, LLC is a Delaware limited liability company.

     

    (d) Title of Class of Securities

    Common Stock

     

    (e) CUSIP Number

    53635D202

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     

     

     

    CUSIP No. 53635D202 13G Page 6 of 7 Pages

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership
       

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: See responses to Item 9 on the attached cover pages.
    (b) Percent of class: See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which the person has:
       
      (i) Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.
      (ii) Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.
      (iii) Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.
      (iv) Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.
             

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       

    Not Applicable

     
     Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
       

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group
       

    Not Applicable

     

    Item 9. Notice of Dissolution of Group
       

    Not Applicable

     

    Item 10. Certification
       

    Not Applicable.

     

     

     

     

    CUSIP No. 53635D202 13G Page 7 of 7 Pages

     

    SIGNATURE

      

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024  
       
      /s/ Paul B. Manning
      Paul B. Manning
         
      PD Joint Holdings, LLC, Series 2016-A
       
      By Tiger Lily Capital, LLC, its manager
       
      By: /s/ Paul B. Manning
      Name: Paul B. Manning
      Title: Manager
         
      By: /s/ Bradford Manning
      Name: Bradford Manning
      Title: Manager
         
      BKB Growth Investments, LLC
       
      By Tiger Lily Capital, LLC, its manager
       
      By: /s/ Paul B. Manning
      Name: Paul B. Manning
      Title: Manager
         
      By: /s/ Bradford Manning
      Name: Bradford Manning
      Title: Manager

     

     

     

    Get the next $LQDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    8/15/2025$43.00Buy
    Jefferies
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    More analyst ratings

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

    MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

    8/5/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

    MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation's request for a preliminary injunction and temporary restraining order in its complaint filed against Liquidia and the first commercial sale of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Liquidia's Chief Financial

    6/23/25 4:34:16 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and COO Kaseta Michael sold $600,132 worth of shares (30,000 units at $20.00), decreasing direct ownership by 7% to 376,412 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    8/7/25 4:30:09 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Adair Jason sold $8,871 worth of shares (454 units at $19.54), decreasing direct ownership by 0.23% to 193,180 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    7/30/25 4:31:13 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Boyle Dana sold $20,771 worth of shares (1,063 units at $19.54), decreasing direct ownership by 0.57% to 186,105 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    7/30/25 4:30:14 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    SEC Filings

    View All

    SEC Form 10-Q filed by Liquidia Corporation

    10-Q - Liquidia Corp (0001819576) (Filer)

    8/12/25 6:45:29 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Liquidia Corp (0001819576) (Filer)

    8/12/25 6:30:44 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    8/5/25 5:02:59 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/16/24 4:05:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/4/24 5:51:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    12/18/23 5:02:01 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    View All

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

    7/21/22 4:30:00 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

    MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

    8/5/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

    MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

    5/1/25 8:00:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

    SC 13G/A - Liquidia Corp (0001819576) (Subject)

    11/12/24 5:35:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/12/24 4:22:57 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/4/24 5:51:42 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

    12/20/24 7:42:58 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care